Evidence map›Paper›PMID 28542563›Full record

ArticlePloS one2017

Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.

Sif Holmboe, Pernille Lund Hansen, Helge Thisgaard, Ines Block, Carolin Müller, Niels Langkjær, Poul Flemming Høilund-Carlsen, Birgitte Brinkmann Olsen, Jan Mollenhauer

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Aptamers in Non-Small Cell Lung Cancer Treatment.Molecules (Basel, Switzerland) · 2020
    Review
  6. Article
  7. Article
  8. Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sif HolmboeLundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense, Denmark.
Pernille Lund HansenLundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense, Denmark.ORCID http://orcid.org/0000-0001-8284-4917
Helge ThisgaardDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Ines BlockLundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense, Denmark.
Carolin MüllerLundbeckfonden Center of Excellence NanoCAN, University of Southern Denmark, Odense, Denmark.
Niels LangkjærDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Poul Flemming Høilund-CarlsenDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Birgitte Brinkmann OlsenDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Jan MollenhauerMolecular Oncology, University of Southern Denmark, Odense, Denmark.
University of Southern Denmark · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells represent the putative tumor-driving subpopulation thought to account for drug resistance, relapse, and metastatic spread of epithelial and other cancer types. Accordingly, cell surface markers for therapeutic delivery to cancer stem cells are subject of intense research. Somatostatin receptor 2 and nucleolin are known to be overexpressed by various cancer types, which have elicited comprehensive efforts to explore their therapeutic utilization. Here, we evaluated somatostatin receptor 2 targeting and nucleolin targeting for therapeutic delivery to cancer stem cells from lung cancer. Nucleolin is expressed highly but not selectively, while somatostatin receptor 2 is expressed selectively but not highly by cancer cells. The non-small cell lung cancer cell lines A549 and H1299, displayed average levels of both surface molecules as judged based on analysis of a larger cell line panel. H1299 compared to A549 cells showed significantly elevated sphere-forming capacity, indicating higher cancer stem cell content, thus qualifying as suitable test system. Nucleolin-targeting 57Co-DOTA-AS1411 aptamer showed efficient internalization by cancer cells and, remarkably, at even higher efficiency by cancer stem cells. In contrast, somatostatin receptor 2 expression levels were not sufficiently high in H1299 cells to confer efficient uptake by either non-cancer stem cells or cancer stem cells. The data provides indication that the nucleolin-targeting AS1411 aptamer might be used for therapeutic delivery to non-small cell lung cancer stem cells.

Indexed as

ApoptosisAptamers, NucleotideCarcinoma, Non-Small-Cell LungCell ProliferationDrug Delivery SystemsHeterocyclic Compounds, 1-RingHumansLung NeoplasmsNeoplastic Stem CellsNucleolinPhosphoproteinsReceptors, SomatostatinRNA-Binding ProteinsSomatostatinTumor Cells, Cultured1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAptamers, NucleotideHeterocyclic Compounds, 1-RingNucleolinPhosphoproteinsReceptors, SomatostatinRNA-Binding ProteinsSomatostatinsomatostatin receptor 2

Identifiers

PMID28542563
PMCPMC5440050
OpenAlexW2618055946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.